These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 14621866)
1. Japanese study of kidney transplantation: 1. Results of early phase II study. Transpl Int; 1992; 5 Suppl 1():S524-8. PubMed ID: 14621866 [TBL] [Abstract][Full Text] [Related]
2. Japanese study of FK 506 on kidney transplantation: 2. Follow-up study of FK 506-treated patients. Transpl Int; 1992; 5 Suppl 1():S552-5. PubMed ID: 14621874 [TBL] [Abstract][Full Text] [Related]
3. Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. Transpl Int; 1994; 7 Suppl 1():S247-51. PubMed ID: 11271216 [TBL] [Abstract][Full Text] [Related]
4. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. Kokado Y; Takahara S; Kyo M; Ichimaru N; Toki K; Wang JD; Okuyama A Transplant Proc; 1999; 31(1-2):1151-4. PubMed ID: 10083515 [No Abstract] [Full Text] [Related]
5. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989 [TBL] [Abstract][Full Text] [Related]
6. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients. Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of tacrolimus in adult renal transplant recipients. Naik P; Madhavarapu M; Mayur P; Nayak KS; Sritharan V Drug Metabol Drug Interact; 2012; 27(3):151-5. PubMed ID: 23089531 [TBL] [Abstract][Full Text] [Related]
8. Current advantage of FK 506 in cadaveric kidney transplantation. Ciancio G; Rosen A; Loreto-Grand B; Burke G; Siquijor A; Luque C; Esquenazi V; Miller J Transplant Proc; 1996 Apr; 28(2):1000-1. PubMed ID: 8623207 [No Abstract] [Full Text] [Related]
9. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Chan L; Hartmann E; Cibrik D; Cooper M; Shaw LM Transplantation; 2010 Jul; 90(1):31-7. PubMed ID: 20517177 [TBL] [Abstract][Full Text] [Related]
10. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718 [TBL] [Abstract][Full Text] [Related]
11. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Morris-Stiff G; Singh J; Ostrowski K; Balaji V; Moore R; Darby C; Lord R; Jurewicz WA Transplant Proc; 1998 Jun; 30(4):1295-6. PubMed ID: 9636525 [No Abstract] [Full Text] [Related]
12. Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. Budde K; Fritsche L; Mai I; Bauer S; Smettan S; Waiser J; Hofmann T; Hauser I; Reinke P; Neumayer HH Int J Clin Pharmacol Ther; 1996 Nov; 34(11):493-7. PubMed ID: 8937932 [TBL] [Abstract][Full Text] [Related]
13. Long-term comparison of tacrolimus and cyclosporine-based immunosuppression in kidney recipients with grafts from non-heart-beating cadaver donor. Kinukawa T; Ohshima S; Ono Y; Fujita T; Hattori R; Tanaka K Transplant Proc; 1998 Jun; 30(4):1227-9. PubMed ID: 9636498 [No Abstract] [Full Text] [Related]
14. Non-heart-beating donor kidney transplantation under tacrolimus immunosuppression. Toda F; Tanabe K; Tokumoto T; Ishikawa N; Koga S; Ito S; Yagisawa T; Toma H Transplant Proc; 2000 Nov; 32(7):1726-9. PubMed ID: 11119909 [No Abstract] [Full Text] [Related]
16. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system. Spence MM; Nguyen LM; Hui RL; Chan J Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Miller J; Mendez R; Pirsch JD; Jensik SC Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543 [TBL] [Abstract][Full Text] [Related]
18. Malabsorption of tacrolimus in kidney transplant recipients: a Japanese single center experience. Tanabe K; Tokumoto T; Ishikawa N; Shimizu T; Okuda H; Ito S; Shinmura H; Inui M; Harano M; Manu M; Koga S; Shiroyanagi Y; Goya N; Yagisawa T; Fuchinoue S; Toma H Transplant Proc; 2000 Nov; 32(7):1718-20. PubMed ID: 11119906 [No Abstract] [Full Text] [Related]